Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: A debated clinical issue

Gynecological Endocrinology

Volumn 25, Issue 12, 2009, Pages 807-815

  Gadducci, Angiolo ^a   Biglia, Nicoletta ^b   Cosio, Stefania ^a   Sismondi, Piero ^b   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer; Dydrogesterone; Growth factor; Hormone replacement therapy; Medroxyprogesterone acetate; Micronised progesterone; Progestin

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE 1; AROMATASE; CHLORMADINONE ACETATE; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; DYDROGESTERONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; MIFEPRISTONE; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; PLACEBO; PROGESTERONE; RALOXIFENE; SULFATASE; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST; BREAST CANCER; BREAST SURGERY; CANCER CELL; CANCER INCIDENCE; CANCER RISK; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; DNA FLANKING REGION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HORMONE SUBSTITUTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONKEY; NONHUMAN; OVARIECTOMY; PARTIAL MASTECTOMY; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT DURATION;

BREAST NEOPLASMS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; POSTMENOPAUSE; PROGESTINS; RISK;

EID: 70450219478     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590903056878     Document Type: Review

References (94)

1. Lamb R, Harrison H, Clarke RB. Mammary development, carcinomas and progesterone: Role of Wnt signalling. Ernst Schering Found Symp Proc 2007;1:1-23.
2. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Aspects of progestin activity on the breast: European Progestin Club. Maturitas 1998;29:61-65.
3. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002; 346:340-352.
4. Seeger H, Wallwiener D, Mueck AO. The effect of progesterone and synthetic progestins on serum- and estradiolstimulated proliferation of human breast cancer cells. Horm Metab Res 2003;35:76-80. (Pubitemid 36583677)
5. Gadducci A, Biglia N, Sismondi P, Genazzani AR. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol 2005;20:343-360.
6. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 without breast cancer. Lancet 1997;350:1047-1059.
7. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int J Cancer 1999;81:339-344.
8. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283:485-491. (Pubitemid 30062864)
9. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: Estrogens versus estrogen plus progestin. J Natl Cancer Inst 2000;92: 328-332.
10. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002;287:734-741. (Pubitemid 34250459)
11. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002;100:1148-1158.
12. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. ; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
13. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002;95:2455-2464.
14. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
15. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97: 1387-1392. (Pubitemid 36297767)
16. Position Statement. Role of progestogen in hormone therapy for postmenopausal women: Position statement of the North American Monopause Society. Menopause 2003; 10:113-132.
17. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al.; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
18. Blake J. Menopause: Evidence-based practice. Best Pract Res Clin Obstet Gynaecol 2006;20:799-839.
19. Beral V, Reeves G, Banks E. Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. BJOG 2005;112:692-695.
20. Kenemans P. Postmenopausal hormone therapy and breast cancer: what is the problem? Maturitas 2005;51:75-82.
21. Tannen RL, Weiner MG, Xie D, Barnhart K. Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod 2007;22:1769-1777.
22. Opatrny L, Dell'Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008;115:169-175. (Pubitemid 350233601)
23. Cuzick J. Hormone replacement therapy and the risk of breast cancer. Eur J Cancer, in press.
24. de Lignières B, de Vathaire F, Fournier S, Urbinelli R, Allaert F, Le MG, Kuttenn F. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 2002;5:332-340.
25. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 2005;96:95-108. (Pubitemid 41096673)
26. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448-454. (Pubitemid 40279968)
27. Dinger JC, Heinemann LA, Mohner S, Thai do M, Assmann A. Breast cancer risk associated with different HRT formulations: A register-based case-control study. BMC Womens Health 2006;12:6-13.
28. L'hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol+progesterone be a safer postmenopausal HRT? A review. Maturitas 2008;60:185-201.
29. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-111.
30. Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000;5:107-115.
31. Cheskis BJ. Regulation of cell signalling cascades by steroid hormones. J Cell Biochem 2004;93:20-27.
32. Song RX, Zhang Z, Chen Y, Bao Y, Santen RJ. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 2007; 148:4091-4101.
33. Kyo S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, Orimo A, Inoue M. Estrogen activates telomerase. Cancer Res 1999;59:5917-5921.
34. Gao J, Chen D, Tian Y, Zhang J, Cai K. Effect of estrogen on telomerase activity in human breast cancer cells. J Huazhong Univ Sci Technol Med Sci 2003;23:286-287.
35. Bayne S, Liu JP. Hormones and growth factors regulate telomerase activity in ageing and cancer. Mol Cell Endocrinol 2005;240:11-22.
36. Mart?́nez-Campa CM, Alonso-González C, Mediavilla MD, Cos S, González A, Sanchez-Barcelo EJ. Melatonin downregulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett 2008;268:272-277.
37. Mitropoulou TN, Tzanakasis GN, Kletsas D, Kalofonos HP, Karamanos NK. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer 2003;104:155-160.
38. Abdallah MA, Abdullah HI, Kang S, Taylor DD, Nakajima ST, Gercel-Taylor C. Effects of the components of hormone therapy on matrix metalloproteinases in breast-cancer cells: An in vitro study. Fertil Steril 2007;87:978-981.
39. Takei H, Lee ES, Jordan VC. In vitro regulation of vascular endothelial growth factorby estrogens andantiestrogens inestrogenreceptor positive breast cancer. Breast Cancer 2002;9:39-42.
40. Garvin S, Nilsson UW, Huss FR, Kratz G, Dabrosin C. Estradiol increases VEGF in human breast studied by wholetissue culture. Cell Tissue Res 2006;325:245-251.
41. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984;36:245-276.
42. Kawagoe J, Ohmichi M, Takahashi T, Ohshima C, Mabuchi S, Takahashi K, Igarashi H, Mori-Abe A, Saitoh M, Du B, Ohta T, et al. Raloxifene inhibits estrogen-induced upregulation of telomerase activity in a human breast cancer cell line. J Biol Chem 2003;278:43363-43372.
43. Gadducci A, Cosio S, Genazzani AR. Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. Curr Opin Invest Drug 2004;5:1031-1044.
44. Qu Z, Van Ginkel S, Roy AM, Westbrook L, Nasrin M, Maxuitenko Y, Frost AR, Carey D, Wang W, Li R, et al. Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. Cancer Res 2008;68:6232-6240.
45. Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, Biglia N, Sismondi P, Genazzani AR, et al. Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS ONE 2008;21;3:e2238.
46. Manni A, Badger B, Wright C, Ahmed SR, Demers LM. Effects of progestins on growth of experimental breast cancer in culture: Interaction with estradiol and prolactin and involvement of the polyamine pathway. Cancer Res 1987; 47:3066-3071.
47. Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA, Horwitz KB. Biphasic regulation of breast cancer cell growth by progesterone: Role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 1997;11:1593-1607.
48. Lange CA, Richer JK, Shen T, Horwitz KB. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 1998;273:31308-31316.
49. Moore MR, Conover JL, Franks KM. Progestin effects on long-term growth, death, and Bcl-xL in breast cancer cells. Biochem Biophys Res Commun 2000;277:650-654.
50. Shen T, Horwitz KB, Lange CA. Transcriptional hyperactivity of human progesterone receptors is coupled to their liganddependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol 2001;21:6122-6131.
51. Moore MR. A rationale for inhibiting progesterone-related pathways to combat breast cancer. Curr Cancer Drug Targets 2004;4:183-189.
52. Sitruk-Ware R, Plu-Bureau G. Exogenous progestogens and the human breast. Maturitas 2004;49:58-66.
53. Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992;52:6539-6546.
54. Markiewicz L, Hochberg RB, Gurpide E. Intrinsic estrogenicity of some progestagenic drugs. J. Steroid Biochem Mol Biol 1992;41:53-58.
55. Gadducci A, Genazzani AR. Steroid hormones in endometrial and breast cancer. Eur J Gynaecol Oncol 1997;18:371-378.
56. Rabe T, Bohlmann MK, Rehberger-Schneider S, Prifti S. Induction of estrogen receptor-alpha and -beta activities by synthetic progestins. Gynecol Endocrinol 2000;14:118-126.
57. Pasqualini JR, Chetrite GS. Endocrine, paracrine and intracrine mechanisms of growth regulation in normal and malignant breast epithelium. In: Genazzani AR, editor. Hormone replacement therapy and cancer. The Current status of research and practice. Boca Raton: Parthenon Publishing; 2002. pp 44-53.
58. Sutherland RL, Prall OWJ, Watts CKW, Musgrove EA. Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 1998;3:63-72.
59. Musgrove EA, Lee CS, Cornish AL, Swarbrick A, Sutherland RL. Antiprogestin inhibition of cell cycle progression in T- 47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 1997;11:54-66.
60. Lange CA, Richer JK, Horwitz KB. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 1999;13:829-836.
61. Musgrove EA, Lee CS, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor a, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991;11:5032-5043.
62. Hurd C, Khattree N, Alban P, Nag K, Jhanwar SC, Dinda S, Moudgil VK. Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line. J Biol Chem 1995;270:28507-28510.
63. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998;17:2008-2018.
64. Castoria G, Barone MV, Di Domenico M, Bilancio A, Ametrano D, Migliaccio A, Auricchio F. Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J 1999;18:2500-2510.
65. Ballare C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A, Auricchio F, Beato M. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 2003;23:1994-2008.
66. Myoui A, Nishimura R, Williams PJ, Hiraga T, Tamura D, Michigami T, Mundy GR, Yoneda T. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003;63:5028-5033.
67. Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D. ErbB2 promotes Src synthesis and stability: Novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res 2005;65:1858-1867.
68. Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D, Susa M, Fabbro D, Bologna M, Teti A. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: Implications for therapy. J Pharmacol Exp Ther 2006;318: 161-172.
69. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;297:263-274.
70. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22: 337-358.
71. Shupnik MA. Crosstalk between steroid receptors and the c- Src-receptor tyrosine kinase pathways: Implications for cell proliferation. Oncogene 2004;23:7979-7989.
72. Carnevale RP, Proietti CJ, Salatino M, Urtreger A, Peluffo G, Edwards DP, Boonyaratanakornkit V, Charreau EH, Bal de Kier Joffé E, Schillaci R, et al. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol 2007;21:1335-1358.
73. Fu XD, Giretti MS, Baldacci C, Garibaldi S, Flamini M, Sanchez AM, Gadducci A, Genazzani AR, Simoncini T. Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS ONE 2008;3:e2790.
74. Foidart JM, Colin C, Denoo X, Desreux J, Be'liard A, Fournier S, de Lignieres B. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-969.
75. Chang KJ, Lee TTY, Linares-Cruz G, Fournier S, de Lignieres B. Influences of percutaneous administration of estradiol and progesterone of human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785-791.
76. Xu B, Kitawaki J, Koshiba H, Ishihara H, Kiyomizu M, Teramoto M, Kitaoka Y, Honjo H. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells.Maturitas 2007;56:142-152.
77. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007; 101:125-134.
78. Wood CE, Register TC, Cline JM. Transcriptional profiles of progestogen effects in the postmenopausal breast. Breast Cancer Res Treat, in press.
79. Campagnoli C, Abbà C, Ambroggio S, Peris C. Differential effects of progestins on the circulating IGF-I system. Maturitas 2003;46S:S39-S44.
80. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396. (Pubitemid 28209997)
81. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-832.
82. Campagnoli C, Biglia N, Lanza MG, Lesca L, Peris C, Sismondi P. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. Maturitas 1994;19:25-31.
83. Fonseca E, Ochoa R, Galván R, Hernández M, Mercado M, Zárate A. Increased serum levels of growth hormone and insulin-like growth factor-I associated with simultaneous decrease of circulating insulin in postmenopausal women receiving hormone replacement therapy. Menopause 1999;6: 56-60.
84. Heald A, Selby PL, White A, Gibson JM. Progestins abrogate estrogen-induced changes in the insuline-like growth factor axis. Am J Obstet Gynecol 2000;183:593-600.
85. Posaci C, Altunyurt S, Islekel H, Onvural A. Effects of HRT on serum levels of IGF-I in postmenopausal women. Maturitas 2001;40:69-74.
86. Campagnoli C, Colombo P, De Aloysio D, Gambacciani M, Grazioli I, Nappi C, Serra GB, Genazzani AR. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas 2002;41:299-311.
87. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, et al.; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253. (Pubitemid 37430077)
88. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: A hypothesis. J Clin Endocrinol Metab 2008;93:3295-3298.
89. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
90. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
91. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100: 3983-3988. (Pubitemid 36418143)
92. Sartorius CA, Harvell DM, Shen T, Horwitz KB. Progestins initiate a luminal to myoepithelial switch in estrogendependent human breast tumors without altering growth. Cancer Res 2005;65:9779-9788.
93. Clarke RB. Ovarian steroids and the human breast: Regulation of stem cells and cell proliferation. Maturitas 2006;54:327-334.
94. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA 2008;105:5774-5779.